Upadacitinib in daily practice for refractory atopic dermatitis in adolescents: a case series of the BioDay registry

Florence Vroman; Lisa P van der Rijst; Octavian I Bacoş-Cosma; Nicolaas P A Zuithoff; Marijke Kamsteeg; Paula P M van Lumig; Laura Loman; Marie-Louise L A Schuttelaar; Marjolein S de Bruin-Weller; Marlies de Graaf

doi:10.1080/09546634.2025.2539282

Upadacitinib in daily practice for refractory atopic dermatitis in adolescents: a case series of the BioDay registry

Florence Vroman
, Lisa P van der Rijst
, Octavian I Bacoş-Cosma
, Nicolaas P A Zuithoff
, Marijke Kamsteeg
, Paula P M van Lumig
, Laura Loman
, Marie-Louise L A Schuttelaar
, Marjolein S de Bruin-Weller
, Marlies de Graaf^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

88 Downloads (Pure)

Abstract

PURPOSE: Upadacitinib is approved for treating moderate-to-severe atopic dermatitis (AD) aged ≥12 years. We evaluated upadacitinib's effectiveness and safety in AD adolescents in daily practice.

MATERIALS AND METHODS: Fifteen adolescent AD patients from the BioDay registry, treated with upadacitinib 15 mg once daily were evaluated at baseline and after 4, 8, 16, and 28 weeks. Effectiveness was assessed using Eczema Area and Severity Index (EASI) score and Investigator Global Assessment (IGA) score. Patient-reported outcomes included Numeric Rating Scale (NRS) for pruritus and presence of sleep disturbance. Adverse events (AEs) were evaluated at each visit.

RESULTS: Mean EASI score significantly decreased from 13.4 (95% CI 8.5-18.3) to 7.8 (95% CI 2.4-13.3) after 28 weeks (p = .002). Mean NRS pruritus significantly decreased from 6.5 (95% CI 4.9-8.2) to 4.8 (95% CI 3.0-6.6) after 28 weeks (p = .003). At week 16, 75.0% (95% CI 46.8-91.1) achieved EASI ≤7, and 50.0% (95% CI 25.4-74.6) achieved NRS pruritus ≤4. Overall, 31 AEs were reported in 10 patients (66.7%). Five patients (33.3%) discontinued treatment: two due to ineffectiveness, two due to AEs, and one due to laboratory monitoring problems.

CONCLUSIONS: Our findings indicate that upadacitinib is effective and relatively safe for adolescents with moderate-to-severe AD; however, 33.3% discontinued treatment.

Original language	English
Article number	2539282
Pages (from-to)	1-6
Number of pages	6
Journal	The journal of dermatological treatment
Volume	36
Issue number	1
DOIs	https://doi.org/10.1080/09546634.2025.2539282
Publication status	Published - Dec 2025

Keywords

Adolescent
Dermatitis, Atopic/drug therapy
Dermatologic Agents/adverse effects
Female
Heterocyclic Compounds, 3-Ring/adverse effects
Humans
Male
Patient Reported Outcome Measures
Pruritus/drug therapy
Registries
Severity of Illness Index
Sleep Wake Disorders/chemically induced
Treatment Outcome

Access to Document

10.1080/09546634.2025.2539282Licence: CC BY-NC

Upadacitinib in daily practice for refractory atopic dermatitis in adolescents a case series of the BioDay registryFinal published version, 2.83 MBLicence: CC BY-NC

Cite this

Vroman, F., van der Rijst, L. P., Bacoş-Cosma, O. I., Zuithoff, N. P. A., Kamsteeg, M., van Lumig, P. P. M., Loman, L., Schuttelaar, M.-L. L. A., de Bruin-Weller, M. S., & de Graaf, M. (2025). Upadacitinib in daily practice for refractory atopic dermatitis in adolescents: a case series of the BioDay registry. The journal of dermatological treatment, 36(1), 1-6. Article 2539282. https://doi.org/10.1080/09546634.2025.2539282

@article{fb41a3fcaffe4aa4bb34374ea7f213a1,

title = "Upadacitinib in daily practice for refractory atopic dermatitis in adolescents: a case series of the BioDay registry",

abstract = "PURPOSE: Upadacitinib is approved for treating moderate-to-severe atopic dermatitis (AD) aged ≥12 years. We evaluated upadacitinib's effectiveness and safety in AD adolescents in daily practice.MATERIALS AND METHODS: Fifteen adolescent AD patients from the BioDay registry, treated with upadacitinib 15 mg once daily were evaluated at baseline and after 4, 8, 16, and 28 weeks. Effectiveness was assessed using Eczema Area and Severity Index (EASI) score and Investigator Global Assessment (IGA) score. Patient-reported outcomes included Numeric Rating Scale (NRS) for pruritus and presence of sleep disturbance. Adverse events (AEs) were evaluated at each visit.RESULTS: Mean EASI score significantly decreased from 13.4 (95\% CI 8.5-18.3) to 7.8 (95\% CI 2.4-13.3) after 28 weeks (p = .002). Mean NRS pruritus significantly decreased from 6.5 (95\% CI 4.9-8.2) to 4.8 (95\% CI 3.0-6.6) after 28 weeks (p = .003). At week 16, 75.0\% (95\% CI 46.8-91.1) achieved EASI ≤7, and 50.0\% (95\% CI 25.4-74.6) achieved NRS pruritus ≤4. Overall, 31 AEs were reported in 10 patients (66.7\%). Five patients (33.3\%) discontinued treatment: two due to ineffectiveness, two due to AEs, and one due to laboratory monitoring problems.CONCLUSIONS: Our findings indicate that upadacitinib is effective and relatively safe for adolescents with moderate-to-severe AD; however, 33.3\% discontinued treatment.",

keywords = "Adolescent, Dermatitis, Atopic/drug therapy, Dermatologic Agents/adverse effects, Female, Heterocyclic Compounds, 3-Ring/adverse effects, Humans, Male, Patient Reported Outcome Measures, Pruritus/drug therapy, Registries, Severity of Illness Index, Sleep Wake Disorders/chemically induced, Treatment Outcome",

author = "Florence Vroman and \{van der Rijst\}, \{Lisa P\} and Baco{\c s}-Cosma, \{Octavian I\} and Zuithoff, \{Nicolaas P A\} and Marijke Kamsteeg and \{van Lumig\}, \{Paula P M\} and Laura Loman and Schuttelaar, \{Marie-Louise L A\} and \{de Bruin-Weller\}, \{Marjolein S\} and \{de Graaf\}, Marlies",

note = "Publisher Copyright: {\textcopyright} 2025 The Author(s). Published with license by Taylor \& Francis Group, LLC.",

year = "2025",

month = dec,

doi = "10.1080/09546634.2025.2539282",

language = "English",

volume = "36",

pages = "1--6",

journal = "The journal of dermatological treatment",

issn = "0954-6634",

publisher = "Taylor and Francis Ltd.",

number = "1",

}

Vroman, F, van der Rijst, LP, Bacoş-Cosma, OI, Zuithoff, NPA, Kamsteeg, M, van Lumig, PPM, Loman, L, Schuttelaar, M-LLA, de Bruin-Weller, MS & de Graaf, M 2025, 'Upadacitinib in daily practice for refractory atopic dermatitis in adolescents: a case series of the BioDay registry', The journal of dermatological treatment, vol. 36, no. 1, 2539282, pp. 1-6. https://doi.org/10.1080/09546634.2025.2539282

TY - JOUR

T1 - Upadacitinib in daily practice for refractory atopic dermatitis in adolescents

T2 - a case series of the BioDay registry

AU - Vroman, Florence

AU - van der Rijst, Lisa P

AU - Bacoş-Cosma, Octavian I

AU - Zuithoff, Nicolaas P A

AU - Kamsteeg, Marijke

AU - van Lumig, Paula P M

AU - Loman, Laura

AU - Schuttelaar, Marie-Louise L A

AU - de Bruin-Weller, Marjolein S

AU - de Graaf, Marlies

PY - 2025/12

Y1 - 2025/12

N2 - PURPOSE: Upadacitinib is approved for treating moderate-to-severe atopic dermatitis (AD) aged ≥12 years. We evaluated upadacitinib's effectiveness and safety in AD adolescents in daily practice.MATERIALS AND METHODS: Fifteen adolescent AD patients from the BioDay registry, treated with upadacitinib 15 mg once daily were evaluated at baseline and after 4, 8, 16, and 28 weeks. Effectiveness was assessed using Eczema Area and Severity Index (EASI) score and Investigator Global Assessment (IGA) score. Patient-reported outcomes included Numeric Rating Scale (NRS) for pruritus and presence of sleep disturbance. Adverse events (AEs) were evaluated at each visit.RESULTS: Mean EASI score significantly decreased from 13.4 (95% CI 8.5-18.3) to 7.8 (95% CI 2.4-13.3) after 28 weeks (p = .002). Mean NRS pruritus significantly decreased from 6.5 (95% CI 4.9-8.2) to 4.8 (95% CI 3.0-6.6) after 28 weeks (p = .003). At week 16, 75.0% (95% CI 46.8-91.1) achieved EASI ≤7, and 50.0% (95% CI 25.4-74.6) achieved NRS pruritus ≤4. Overall, 31 AEs were reported in 10 patients (66.7%). Five patients (33.3%) discontinued treatment: two due to ineffectiveness, two due to AEs, and one due to laboratory monitoring problems.CONCLUSIONS: Our findings indicate that upadacitinib is effective and relatively safe for adolescents with moderate-to-severe AD; however, 33.3% discontinued treatment.

AB - PURPOSE: Upadacitinib is approved for treating moderate-to-severe atopic dermatitis (AD) aged ≥12 years. We evaluated upadacitinib's effectiveness and safety in AD adolescents in daily practice.MATERIALS AND METHODS: Fifteen adolescent AD patients from the BioDay registry, treated with upadacitinib 15 mg once daily were evaluated at baseline and after 4, 8, 16, and 28 weeks. Effectiveness was assessed using Eczema Area and Severity Index (EASI) score and Investigator Global Assessment (IGA) score. Patient-reported outcomes included Numeric Rating Scale (NRS) for pruritus and presence of sleep disturbance. Adverse events (AEs) were evaluated at each visit.RESULTS: Mean EASI score significantly decreased from 13.4 (95% CI 8.5-18.3) to 7.8 (95% CI 2.4-13.3) after 28 weeks (p = .002). Mean NRS pruritus significantly decreased from 6.5 (95% CI 4.9-8.2) to 4.8 (95% CI 3.0-6.6) after 28 weeks (p = .003). At week 16, 75.0% (95% CI 46.8-91.1) achieved EASI ≤7, and 50.0% (95% CI 25.4-74.6) achieved NRS pruritus ≤4. Overall, 31 AEs were reported in 10 patients (66.7%). Five patients (33.3%) discontinued treatment: two due to ineffectiveness, two due to AEs, and one due to laboratory monitoring problems.CONCLUSIONS: Our findings indicate that upadacitinib is effective and relatively safe for adolescents with moderate-to-severe AD; however, 33.3% discontinued treatment.

KW - Adolescent

KW - Dermatitis, Atopic/drug therapy

KW - Dermatologic Agents/adverse effects

KW - Female

KW - Heterocyclic Compounds, 3-Ring/adverse effects

KW - Humans

KW - Male

KW - Patient Reported Outcome Measures

KW - Pruritus/drug therapy

KW - Registries

KW - Severity of Illness Index

KW - Sleep Wake Disorders/chemically induced

KW - Treatment Outcome

U2 - 10.1080/09546634.2025.2539282

DO - 10.1080/09546634.2025.2539282

M3 - Article

C2 - 40739850

SN - 0954-6634

VL - 36

SP - 1

EP - 6

JO - The journal of dermatological treatment

JF - The journal of dermatological treatment

IS - 1

M1 - 2539282

ER -

Upadacitinib in daily practice for refractory atopic dermatitis in adolescents: a case series of the BioDay registry

Abstract

Keywords

Access to Document

Fingerprint

Cite this